A DNA vaccine encoding MUC1 and survivin fusion antigens, VR-MS, increased in vitro killing of MUC1+ survivin+ B16 cells and significantly delayed tumor growth using a 100 μg dose [57]. This evidence concerns the gene MUC1 and neoplasm.